

GLOBAL MARKETS FOR VACCINE TECHNOLOGIES



PHM014F
January 2017

Shalini Shahani Dewan
Project Analyst

ISBN: 1-62296-430-6



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
info@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY OBJECTIVES	2
REASONS FOR DOING THIS STUDY	2
CONTRIBUTIONS OF THE STUDY AND FOR WHOM	3
SCOPE OF THE STUDY	3
METHODOLOGY	3
INFORMATION SOURCES	3
ANALYSTS' CREDENTIALS	3
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	4
DISCLAIMER	5
CHAPTER 2 EXECUTIVE SUMMARY	7
<i>SUMMARY TABLE GLOBAL MARKET FOR VACCINE TECHNOLOGIES, BY SEGMENT, THROUGH 2021 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, 2014-2021 (\$ MILLIONS)</i>	8
CHAPTER 3 OVERVIEW	10
DEFINITIONS	10
THE IMMUNE SYSTEM	11
HOW VACCINES WORK	11
TYPES OF IMMUNITY	12
ACTIVE	12
PASSIVE	12
ADVANTAGES OF VACCINATION	12
HISTORY OF VACCINES	13
<i>TABLE 1 HISTORY OF VACCINES</i>	13
TYPES OF VACCINES	15
ATTENUATED (LIVE) VACCINES	15
Types of Attenuated (Live) Vaccines	15
<i>TABLE 2 TYPES OF ATTENUATED (LIVE) VACCINES</i>	16
Advantages and Disadvantages of Attenuated (Live) Vaccines	17
<i>TABLE 3 ADVANTAGES AND DISADVANTAGES OF ATTENUATED (LIVE) VACCINES</i>	17
INACTIVATED (KILLED) VACCINES	17
Types of Inactivated (Killed) Vaccines	18
<i>TABLE 4 TYPES OF INACTIVATED (KILLED) VACCINES</i>	18
Advantages and Disadvantages of Inactivated (Killed) Vaccines	18
<i>TABLE 5 ADVANTAGES AND DISADVANTAGES OF INACTIVATED (KILLED) VACCINES</i>	19
TOXOID VACCINES	19
Types of Toxoid Vaccines	19
<i>TABLE 6 TYPES OF TOXOID VACCINES</i>	20
Advantages and Disadvantages of Toxoid Vaccines	20
<i>TABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES</i>	20
SUBUNIT VACCINES	21
Types of Subunit Vaccines	21

TOPIC	PAGE NO.
<i>TABLE 8 TYPES OF SUBUNIT VACCINES</i>	21
Advantages and Disadvantages of Subunit Vaccines	22
<i>TABLE 9 ADVANTAGES AND DISADVANTAGES OF SUBUNIT VACCINES</i>	22
CONJUGATE VACCINES	22
Types of Conjugate Vaccines	23
<i>TABLE 10 TYPES OF CONJUGATE VACCINES</i>	23
Advantages and Disadvantages of Conjugate Vaccines	23
<i>TABLE 11 ADVANTAGES AND DISADVANTAGES OF CONJUGATE VACCINES</i>	23
RECOMBINANT VECTOR VACCINES	23
Types of Recombinant Vector Vaccines	24
<i>TABLE 12 TYPES OF RECOMBINANT VECTOR VACCINES</i>	24
Advantages and Disadvantages of Recombinant Vector Vaccines	24
<i>TABLE 13 ADVANTAGES AND DISADVANTAGES OF RECOMBINANT VECTOR VACCINES</i>	25
DNA VACCINES	25
Types of DNA Vaccines	25
<i>TABLE 14 TYPES OF DNA VACCINES</i>	26
Advantages and Disadvantages of DNA vaccines	26
<i>TABLE 15 ADVANTAGES AND DISADVANTAGES OF DNA VACCINES</i>	26
RNA VACCINES	27
<i>TABLE 16 ADVANTAGES AND DISADVANTAGES OF RNA VACCINES</i>	27
<i>FIGURE 1 OVERVIEW OF HOW RNA-BASED VACCINES WORK</i>	27
ADJUVANTS AND EXCIPIENTS	30
PATHOGEN COMPONENTS	31
PARTICULATE ADJUVANTS	31
<i>TABLE 17 VACCINE EXCIPIENT AND MEDIA SUMMARY, EXCIPIENTS INCLUDED IN U.S. VACCINES, BY VACCINE</i>	33
<i>INFECTIOUS DISEASES PREVENTABLE BY VACCINES</i>	38
HUMAN DISEASES	38
Viral Diseases	38
<i>TABLE 18 VACCINE-PREVENTABLE HUMAN VIRAL DISEASES</i>	39
Bacterial Diseases	41
<i>TABLE 19 VACCINE-PREVENTABLE HUMAN BACTERIAL DISEASES</i>	41
ANIMAL DISEASES	44
Food-Producing Animals	45
<i>TABLE 20 VACCINE-PREVENTABLE PARASITIC ANIMAL DISEASES FOUND IN FOOD-PRODUCING ANIMALS</i>	45
<i>TABLE 21 VACCINE-PREVENTABLE BACTERIAL ANIMAL DISEASES FOUND IN FOOD-PRODUCING ANIMALS</i>	46
<i>TABLE 22 VACCINE-PREVENTABLE VIRAL ANIMAL DISEASES FOUND IN FOOD-PRODUCING ANIMALS</i>	47
Companion Animals	48
<i>TABLE 23 VACCINE-PREVENTABLE PARASITIC ANIMAL DISEASES FOUND IN COMPANION ANIMALS</i>	48
<i>TABLE 24 VACCINE-PREVENTABLE BACTERIAL ANIMAL DISEASES FOUND IN COMPANION ANIMALS</i>	48
<i>TABLE 25 VACCINE-PREVENTABLE VIRAL ANIMAL DISEASES FOUND IN COMPANION ANIMALS</i>	49
Other Animals	49

TOPIC	PAGE NO.
<i>TABLE 26 VACCINE-PREVENTABLE VIRAL ANIMAL DISEASES FOUND IN OTHER ANIMALS</i>	50
<i>TABLE 27 ANIMAL VACCINES FOR FOOD-PRODUCING, COMPANION AND OTHER ANIMALS</i>	51
CHAPTER 4 REGULATORY ASPECTS	57
REGULATORY ASPECTS	57
WORLD HEALTH ORGANIZATION (WHO) PREQUALIFIED VACCINES	57
<i>TABLE 28 WHO PREQUALIFIED VACCINES, JANUARY 2014-SEPTEMBER 2016</i>	57
NEW PRODUCT APPROVALS	62
<i>TABLE 29 NEWLY APPROVED VACCINES, 2014-SEPTEMBER 2016</i>	62
RECALLS	62
<i>TABLE 30 GLOBAL VACCINE RECALLS, JANUARY 2014-SEPTEMBER 2016</i>	63
VACCINE SHORTAGE	63
<i>TABLE 31 GLOBAL VACCINE SHORTAGE, JANUARY 2012-SEPTEMBER 2016</i>	63
SIGNIFICANT REGULATORY DEVELOPMENTS IN VACCINE-PREVENTABLE DISEASE PRODUCTS	63
CHAPTER 5 NEW DEVELOPMENTS	66
<i>TABLE 32 HUMAN VACCINES IN THE RESEARCH PIPELINE AS OF SEPTEMBER 2016</i>	66
ALLIANCES AND JOINT VENTURES	69
<i>TABLE 33 ALLIANCES AND JOINT VENTURES FOR THE DEVELOPMENT OF HUMAN AND ANIMAL VACCINES, JANUARY 2014-SEPTEMBER 2016</i>	69
NEW PRODUCT LAUNCHES	71
<i>TABLE 34 NEWLY VACCINES LAUNCHED, JANUARY 2014-SEPTEMBER 2016</i>	71
CHAPTER 6 MARKET ANALYSIS OF HUMAN VACCINES	73
MARKET BY TYPE	74
MARKET OVERVIEW	74
MARKET REVENUE	75
<i>TABLE 35 GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, THROUGH 2021 (\$ MILLIONS)</i>	75
<i>FIGURE 2 GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, 2014-2021 (\$ MILLIONS)</i>	75
MARKET SHARE	76
<i>TABLE 36 GLOBAL MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE, 2015 (%)</i>	76
<i>FIGURE 3 GLOBAL MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE, 2015 (%)</i>	77
MARKET BY REGION	77
MARKET OVERVIEW	77
MARKET REVENUE	78
<i>TABLE 37 GLOBAL SALES OF HUMAN VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	79
<i>FIGURE 4 GLOBAL SALES OF HUMAN VACCINES BY REGION, 2014-2021 (\$ MILLIONS)</i>	79
MARKET SHARE	79
<i>TABLE 38 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY REGION, 2015 (%)</i>	79

TOPIC	PAGE NO.
<i>FIGURE 5 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY REGION, 2015 (%)</i>	80
REGIONAL MARKETS FOR ATTENUATED (LIVE) VACCINES	80
Market Overview	80
Market Revenue	81
<i>TABLE 39 GLOBAL MARKET FOR ATTENUATED (LIVE) VACCINE, BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	82
<i>FIGURE 6 GLOBAL MARKET FOR ATTENUATED (LIVE) VACCINE BY REGION, 2014-2021 (\$ MILLIONS)</i>	82
REGIONAL MARKETS FOR INACTIVATED VACCINES	83
Market Overview	83
Market Revenue	83
<i>TABLE 40 GLOBAL MARKET FOR INACTIVATED (KILLED) VACCINES, BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	84
<i>FIGURE 7 GLOBAL MARKET FOR INACTIVATED (KILLED) VACCINES BY REGION, 2014-2021 (\$ MILLIONS)</i>	84
REGIONAL MARKETS FOR CONJUGATE VACCINES	85
Market Overview	85
Market Revenue	86
<i>TABLE 41 GLOBAL MARKET FOR CONJUGATE VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	87
<i>FIGURE 8 GLOBAL MARKET FOR CONJUGATE VACCINES BY REGION, 2014-2021 (\$ MILLIONS)</i>	87
REGIONAL MARKETS FOR RDNA/ DNA VACCINES	88
Market Overview	88
Market Revenue	89
<i>TABLE 42 GLOBAL MARKET FOR RECOMBINANT/RDNA/DNA VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	89
<i>FIGURE 9 GLOBAL MARKET FOR RECOMBINANT/RDNA/DNA VACCINES BY REGION, 2014-2021 (\$ MILLIONS)</i>	90
REGIONAL MARKETS FOR SUBUNIT VACCINES	90
Market Overview	91
Market Revenue	91
<i>TABLE 43 GLOBAL MARKET FOR SUBUNIT VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	92
<i>FIGURE 10 GLOBAL MARKET FOR SUBUNIT VACCINES BY REGION, 2014-2021 (\$ MILLIONS)</i>	92
REGIONAL MARKETS FOR TOXOID VACCINES	92
Market Overview	93
Market Revenue	93
<i>TABLE 44 GLOBAL MARKET FOR TOXOID VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	93
<i>FIGURE 11 GLOBAL MARKET FOR TOXOID VACCINES BY REGION, 2014-2021 (\$ MILLIONS)</i>	94
REGIONAL MARKETS FOR OTHER/COMBINATION VACCINES	94
Market Overview	94
Market Revenue	95
<i>TABLE 45 GLOBAL MARKET FOR OTHER/COMBINATION VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	95

TOPIC	PAGE NO.
<i>FIGURE 12 GLOBAL MARKET FOR OTHER/COMBINATION VACCINES BY REGION, 2014-2021 (\$ MILLIONS)</i>	95
CHAPTER 7 MARKET ANALYSIS OF ANIMAL VACCINES	98
MARKET OVERVIEW	98
MARKET REVENUE	99
<i>TABLE 46 GLOBAL SALES OF ANIMAL HEALTH PRODUCTS BY MARKET LEADER, 2014-2016 (\$ MILLIONS)</i>	100
<i>FIGURE 13 GLOBAL SALES OF ANIMAL HEALTH PRODUCTS BY MARKET LEADER, 2014-2016 (\$ MILLIONS)</i>	100
ANIMAL VACCINES	101
MARKET BY TYPE	103
<i>TABLE 47 GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, THROUGH 2021 (\$ MILLIONS)</i>	103
<i>FIGURE 14 GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, 2014-2021 (\$ MILLIONS)</i>	103
VACCINES USED IN FOOD-PRODUCING ANIMALS	104
Market Overview	104
Market Revenue	107
<i>TABLE 48 GLOBAL MARKET FOR VACCINES FOR FOOD-PRODUCING ANIMALS BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	107
<i>FIGURE 15 GLOBAL MARKET FOR VACCINES FOR FOOD-PRODUCING ANIMALS BY REGION, 2014-2021 (\$ MILLIONS)</i>	108
COMPANION ANIMAL VACCINES	108
Market Overview	108
Market Revenue	109
<i>TABLE 49 GLOBAL MARKET FOR VACCINES FOR COMPANION ANIMALS BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	110
<i>FIGURE 16 GLOBAL MARKET FOR VACCINES FOR COMPANION ANIMALS BY REGION, 2014-2021 (\$ MILLIONS)</i>	110
OTHER ANIMAL VACCINES	111
Market Overview	111
Market Revenue	112
<i>TABLE 50 GLOBAL MARKET FOR OTHER ANIMAL VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	112
<i>FIGURE 17 GLOBAL MARKET FOR OTHER ANIMAL VACCINES BY REGION, 2014-2021 (\$ MILLIONS)</i>	112
MARKET SHARE	113
<i>TABLE 51 GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE, 2015 (%)</i>	113
<i>FIGURE 18 GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE, 2015 (%)</i>	113
MARKET BY REGION	113
MARKET OVERVIEW	114
MARKET REVENUE	114
<i>TABLE 52 GLOBAL SALES OF ANIMAL VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	115
<i>FIGURE 19 GLOBAL SALES OF ANIMAL VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	115
MARKET SHARE	115

TOPIC	PAGE NO.
<i>TABLE 53 GLOBAL MARKET SHARES OF ANIMAL VACCINE SALES BY REGION, 2015 (%)</i>	116
<i>FIGURE 20 GLOBAL MARKET SHARES OF ANIMAL VACCINE SALES BY REGION, 2015 (%)</i>	116
CHAPTER 8 INDUSTRY STRUCTURE	118
MARKET LEADERS IN HUMAN VACCINE	118
<i>TABLE 54 LEADING MANUFACTURERS/ SUPPLIERS OF HUMAN VACCINES</i>	118
MARKET SHARE OF HUMAN VACCINE	124
<i>TABLE 55 GLOBAL MARKET SHARE OF MANUFACTURERS OF HUMAN VACCINE, 2015 (%)</i>	124
<i>FIGURE 21 GLOBAL MARKET SHARE OF MANUFACTURERS OF HUMAN VACCINE, 2015 (%)</i>	124
MARKET LEADERS IN ANIMAL VACCINE	125
<i>TABLE 56 LEADING MANUFACTURERS/SUPPLIERS OF ANIMAL VACCINES</i>	126
MARKET SHARE OF ANIMAL VACCINE	128
<i>TABLE 57 ANIMAL VACCINE MANUFACTURERS' GLOBAL MARKET SHARE, 2015 (%)</i>	129
<i>FIGURE 22 ANIMAL VACCINE MANUFACTURERS GLOBAL MARKET SHARE, 2015 (%)</i>	129
CHAPTER 9 MARKET BY APPLICATION FOR HUMAN VACCINES	131
PROPHYLACTIC VACCINES	131
THERAPEUTIC VACCINES	131
<i>TABLE 58 HUMAN VACCINES BASED ON MICROORGANISM</i>	132
MENINGOCOCCAL/PNEUMOCOCCAL DISEASES	133
MENINGOCOCCAL	133
PNEUMOCOCCAL DISEASES	134
MARKET REVENUE	134
<i>TABLE 59 GLOBAL SALES OF HUMAN VACCINES FOR MENINGOCOCCAL/ PNEUMOCOCCAL DISEASES, THROUGH 2021 (\$ MILLIONS)</i>	135
<i>FIGURE 23 GLOBAL SALES OF HUMAN VACCINES FOR MENINGOCOCCAL/ PNEUMOCOCCAL DISEASES, 2014-2021 (\$ MILLIONS)</i>	135
MARKET SHARE	135
<i>TABLE 60 GLOBAL MARKET SHARES OF TOP-SELLING MENINGOCOCCAL/ PNEUMOCOCCAL VACCINES, 2015 (%)</i>	136
<i>FIGURE 24 GLOBAL MARKET SHARES OF TOP-SELLING MENINGOCOCCAL/ PNEUMOCOCCAL VACCINES, 2015 (%)</i>	136
INFLUENZA (SEASONAL AND PANDEMIC DISEASE)	136
MARKET REVENUE	137
<i>TABLE 61 GLOBAL SALES OF HUMAN VACCINES IN INFLUENZA DISEASES MARKET, THROUGH 2021 (\$ MILLIONS)</i>	138
<i>FIGURE 25 GLOBAL SALES OF HUMAN VACCINES IN INFLUENZA DISEASES MARKET, 2014-2021 (\$ MILLIONS)</i>	138
MARKET SHARE	138
<i>TABLE 62 GLOBAL MARKET SHARES OF TOP-SELLING INFLUENZA VACCINES, 2015 (%)</i>	139
<i>FIGURE 26 GLOBAL MARKET SHARES OF TOP-SELLING INFLUENZA VACCINES, 2015 (%)</i>	139
PEDIATRIC POLIO/PERTUSSIS/HIB	140
MARKET REVENUE	141

TOPIC	PAGE NO.
<i>TABLE 63 GLOBAL MARKET FOR HUMAN VACCINES PEDIATRIC POLIO/PERTUSSIS/HIB DISEASES, THROUGH 2021 (\$ MILLIONS)</i>	142
<i>FIGURE 27 GLOBAL MARKET FOR HUMAN VACCINES PEDIATRIC POLIO/PERTUSSIS/HIB DISEASES MARKET, 2014-2021 (\$ MILLIONS)</i>	142
MARKET SHARE	142
<i>TABLE 64 GLOBAL MARKET SHARES OF TOP-SELLING PEDIATRIC POLIO/PERTUSSIS/HIB VACCINES, 2015 (%)</i>	143
<i>FIGURE 28 GLOBAL MARKET SHARES OF TOP-SELLING PEDIATRIC POLIO/PERTUSSIS/HIB VACCINES, 2015 (%)</i>	143
ADULT/ADOLESCENT BOOSTER VACCINES	143
MARKET REVENUE	144
<i>TABLE 65 GLOBAL MARKET FOR HUMAN VACCINES IN ADULT/ADOLESCENT BOOSTER DISEASES, THROUGH 2021 (\$ MILLIONS)</i>	144
<i>FIGURE 29 GLOBAL MARKET FOR HUMAN VACCINES IN ADULT/ADOLESCENT BOOSTER DISEASES, 2014-2021 (\$ MILLIONS)</i>	145
MARKET SHARE	145
<i>TABLE 66 GLOBAL MARKET SHARES OF TOP-SELLING ADULT/ADOLESCENT BOOSTER VACCINES, 2015 (%)</i>	145
<i>FIGURE 30 GLOBAL MARKET SHARES OF TOP-SELLING ADULT/ADOLESCENT BOOSTER VACCINES, 2015 (%)</i>	145
TRAVEL-RELATED AND OTHER ENDEMIC DISEASES	146
MARKET REVENUE	147
<i>TABLE 67 GLOBAL MARKET FOR HUMAN VACCINES FOR TRAVEL-RELATED AND OTHER ENDEMIC DISEASES, THROUGH 2021 (\$ MILLIONS)</i>	148
<i>FIGURE 31 GLOBAL MARKET FOR HUMAN VACCINES FOR TRAVEL-RELATED AND OTHER ENDEMIC DISEASES, 2014-2021 (\$ MILLIONS)</i>	148
MARKET SHARE	148
<i>TABLE 68 GLOBAL MARKET SHARES OF TOP-SELLING VACCINES FOR TRAVEL-RELATED AND OTHER ENDEMIC DISEASES, 2015 (%)</i>	149
<i>FIGURE 32 GLOBAL MARKET SHARES OF TOP-SELLING VACCINES FOR TRAVEL-RELATED AND OTHER ENDEMIC DISEASES, 2015 (%)</i>	149
HPV DISEASE	149
MARKET REVENUE	151
<i>TABLE 69 GLOBAL MARKET FOR HUMAN VACCINES IN HPV, THROUGH 2021 (\$ MILLIONS)</i>	151
<i>FIGURE 33 GLOBAL MARKET FOR HUMAN VACCINES IN HPV, 2014-2021 (\$ MILLIONS)</i>	151
MARKET SHARE	152
<i>TABLE 70 GLOBAL MARKET SHARES OF TOP-SELLING HPV VACCINES, 2015 (%)</i>	152
<i>FIGURE 34 GLOBAL MARKET SHARES OF TOP-SELLING HPV VACCINES, 2015 (%)</i>	152
ROTAVIRUS DISEASE	153
MARKET REVENUE	154
<i>TABLE 71 GLOBAL MARKET FOR HUMAN VACCINES IN ROTAVIRUS, THROUGH 2021 (\$ MILLIONS)</i>	154
<i>FIGURE 35 GLOBAL MARKET FOR HUMAN VACCINES IN ROTAVIRUS, 2014-2021 (\$ MILLIONS)</i>	154
MARKET SHARE	155
<i>TABLE 72 GLOBAL MARKET SHARES OF TOP-SELLING ROTAVIRUS VACCINES, 2015 (%)</i>	155
<i>FIGURE 36 GLOBAL MARKET SHARES OF TOP-SELLING ROTAVIRUS VACCINES, 2015 (%)</i>	155

TOPIC	PAGE NO.
OTHER DISEASES	155
MARKET REVENUE	156
<i>TABLE 73 GLOBAL MARKET FOR HUMAN VACCINES IN THE OTHER DISEASES SEGMENT, THROUGH 2021 (\$ MILLIONS)</i>	157
<i>FIGURE 37 GLOBAL MARKET FOR HUMAN VACCINES IN THE OTHER DISEASES SEGMENT, 2014-2021 (\$ MILLIONS)</i>	157
MARKET SHARE	158
<i>TABLE 74 GLOBAL MARKET SHARES OF TOP-SELLING VACCINES IN THE OTHER DISEASES SEGMENT, 2015 (%)</i>	158
<i>FIGURE 38 GLOBAL MARKET SHARES OF TOP-SELLING VACCINES IN THE OTHER DISEASES SEGMENT, 2015 (%)</i>	158
MARKET SHARE OF APPLICATIONS	159
<i>TABLE 75 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY APPLICATION, 2015 (%)</i>	159
<i>FIGURE 39 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY APPLICATION, 2015 (%)</i>	160
CHAPTER 10 PATENT ANALYSIS	162
PATENTS BY YEAR	162
<i>TABLE 76 U.S. PATENTS ISSUED FOR VACCINES BY YEAR, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS)</i>	162
<i>FIGURE 40 U.S. PATENTS ISSUED FOR VACCINES BY YEAR, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS)</i>	163
PATENTS BY VACCINE TYPE	163
<i>TABLE 77 U.S. PATENTS BY TYPE OF VACCINES, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS)</i>	163
<i>FIGURE 41 U.S. PATENTS BY TYPE OF VACCINES, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS)</i>	164
PATENTS BY ASSIGNEE'S COUNTRY	164
<i>TABLE 78 U.S. PATENTS BY ASSIGNEE'S COUNTRY, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS)</i>	164
<i>TABLE 79 GLOBAL PATENT SHARES BY PATENT HOLDER'S COUNTRY, JANUARY 2014-SEPTEMBER 2016 (%)</i>	165
<i>FIGURE 42 PATENT SHARES BY PATENT HOLDER'S COUNTRY, JANUARY 2014-SEPTEMBER 2016 (%)</i>	166
PATENTS BY COMPANY	167
<i>TABLE 80 U.S. PATENTS BY COMPANY, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS)</i>	167
PATENTS BY ASSIGNEE	168
<i>TABLE 81 U.S. PATENTS BY ASSIGNEE TYPE, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS)</i>	168
<i>FIGURE 43 U.S. PATENTS BY ASSIGNEE TYPE, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS)</i>	168
CHAPTER 11 CURRENT SITUATION	171
HUMAN VACCINES	171
DEVELOPMENT AND LAUNCH OF NEW VACCINES	172
INCREASED R&D EFFORTS	172
INCREASED DEMAND FROM EMERGING MARKETS	172
GOVERNMENT INITIATIVES FOR INCREASED IMMUNIZATIONS	172

TOPIC	PAGE NO.
HIGH PRICES OF VACCINES	173
PRICING PRESSURE	173
GLOBAL ALLIANCE FOR VACCINES AND IMMUNIZATION (GAVI)	173
RISING CONCERNS OF ASSOCIATED RISK FACTORS	174
INADEQUATE VACCINE SUPPLY	175
COLLABORATIONS, LICENSING AGREEMENTS, MERGERS AND ACQUISITIONS	175
ANIMAL VACCINES	176
CHAPTER 12 COMPANY PROFILES	178
ABBOTT LABORATORIES	178
AERAS GLOBAL	178
ASTELLAS PHARMA INC.	179
ASTRAZENECA PLC	179
BAXTER INTERNATIONAL INC.	180
BAYER ANIMAL HEALTH	181
BHARAT BIOTECH INTERNATIONAL LIMITED	181
BIOLOGICAL E. LTD.	182
BIO-MANGUINHOS	183
BIOPROPERTIES PTY LTD.	183
BOEHRINGER INGELHEIM GMBH	184
BUL BIO - NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES LTD. (BB-NCIPD LTD.)	185
CADILA HEALTHCARE LTD. (ZYDUS CADILA)	185
CEVA SANTE ANIMALE	186
CHINA NATIONAL BIOTEC GROUP (CNBG)	186
COLORADO SERUM COMPANY	187
CSL LIMITED	187
ELANCO ANIMAL HEALTH	188
EMERGENT BIOSOLUTIONS INC.	189
FATRO S.P.A.	190
GENVEC INC.	190
GENEONE LIFE SCIENCES INC	191
GEOVAX	191
GLAXOSMITHKLINE PLC	192
GREEN CROSS CORP	193
INSTITUT PASTEUR DE DAKAR	193
JAPAN BCG LABORATORY	194
LG LIFE SCIENCES	194
JOHNSON AND JOHNSON INC	195
MERCK & CO. INC.	195
MERIAL S.A.S.	196
NOVARTIS PHARMA AG	197
PANACEA BIOTEC LTD.	198
PFENEX INC.	198
PFIZER INC.	199
PROFECTUS BIOSCIENCES INC.	199
PT BIO FARMA	200

TOPIC	PAGE NO.
SANOFI PASTEUR	200
SERUM INSTITUTE OF INDIA LIMITED	201
STATENS SERUM INSTITUT	202
VALNEVA SE	202
VIRBAC	203
ZOETIS INC.	203
CHAPTER 13 APPENDIX I - ABBREVIATIONS	206

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FOR VACCINE TECHNOLOGIES, BY SEGMENT, THROUGH 2021 (\$ MILLIONS)	8
TABLE 1 HISTORY OF VACCINES	13
TABLE 2 TYPES OF ATTENUATED (LIVE) VACCINES	16
TABLE 3 ADVANTAGES AND DISADVANTAGES OF ATTENUATED (LIVE) VACCINES	17
TABLE 4 TYPES OF INACTIVATED (KILLED) VACCINES	18
TABLE 5 ADVANTAGES AND DISADVANTAGES OF INACTIVATED (KILLED) VACCINES	19
TABLE 6 TYPES OF TOXOID VACCINES	20
TABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES	20
TABLE 8 TYPES OF SUBUNIT VACCINES	21
TABLE 9 ADVANTAGES AND DISADVANTAGES OF SUBUNIT VACCINES	22
TABLE 10 TYPES OF CONJUGATE VACCINES	23
TABLE 11 ADVANTAGES AND DISADVANTAGES OF CONJUGATE VACCINES	23
TABLE 12 TYPES OF RECOMBINANT VECTOR VACCINES	24
TABLE 13 ADVANTAGES AND DISADVANTAGES OF RECOMBINANT VECTOR VACCINES	25
TABLE 14 TYPES OF DNA VACCINES	26
TABLE 15 ADVANTAGES AND DISADVANTAGES OF DNA VACCINES	26
TABLE 16 ADVANTAGES AND DISADVANTAGES OF RNA VACCINES	27
TABLE 17 VACCINE EXCIPIENT AND MEDIA SUMMARY, EXCIPIENTS INCLUDED IN U.S. VACCINES, BY VACCINE	33
TABLE 18 VACCINE-PREVENTABLE HUMAN VIRAL DISEASES	39
TABLE 19 VACCINE-PREVENTABLE HUMAN BACTERIAL DISEASES	41
TABLE 20 VACCINE-PREVENTABLE PARASITIC ANIMAL DISEASES FOUND IN FOOD-PRODUCING ANIMALS	45
TABLE 21 VACCINE-PREVENTABLE BACTERIAL ANIMAL DISEASES FOUND IN FOOD-PRODUCING ANIMALS	46
TABLE 22 VACCINE-PREVENTABLE VIRAL ANIMAL DISEASES FOUND IN FOOD-PRODUCING ANIMALS	47
TABLE 23 VACCINE-PREVENTABLE PARASITIC ANIMAL DISEASES FOUND IN COMPANION ANIMALS	48
TABLE 24 VACCINE-PREVENTABLE BACTERIAL ANIMAL DISEASES FOUND IN COMPANION ANIMALS	48
TABLE 25 VACCINE-PREVENTABLE VIRAL ANIMAL DISEASES FOUND IN COMPANION ANIMALS	49
TABLE 26 VACCINE-PREVENTABLE VIRAL ANIMAL DISEASES FOUND IN OTHER ANIMALS	50
TABLE 27 ANIMAL VACCINES FOR FOOD-PRODUCING, COMPANION AND OTHER ANIMALS	51
TABLE 28 WHO PREQUALIFIED VACCINES, JANUARY 2014-SEPTEMBER 2016	57
TABLE 29 NEWLY APPROVED VACCINES, 2014-SEPTEMBER 2016	62
TABLE 30 GLOBAL VACCINE RECALLS, JANUARY 2014-SEPTEMBER 2016	63
TABLE 31 GLOBAL VACCINE SHORTAGE, JANUARY 2012-SEPTEMBER 2016	63
TABLE 32 HUMAN VACCINES IN THE RESEARCH PIPELINE AS OF SEPTEMBER 2016	66
TABLE 33 ALLIANCES AND JOINT VENTURES FOR THE DEVELOPMENT OF HUMAN AND ANIMAL VACCINES, JANUARY 2014-SEPTEMBER 2016	69
TABLE 34 NEWLY VACCINES LAUNCHED, JANUARY 2014-SEPTEMBER 2016	71
TABLE 35 GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, THROUGH 2021 (\$ MILLIONS)	75

TABLE HEADING	PAGE NO.
TABLE 36 GLOBAL MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE, 2015 (%)	76
TABLE 37 GLOBAL SALES OF HUMAN VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)	79
TABLE 38 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY REGION, 2015 (%)	79
TABLE 39 GLOBAL MARKET FOR ATTENUATED (LIVE) VACCINE, BY REGION, THROUGH 2021 (\$ MILLIONS)	82
TABLE 40 GLOBAL MARKET FOR INACTIVATED (KILLED) VACCINES, BY REGION, THROUGH 2021 (\$ MILLIONS)	84
TABLE 41 GLOBAL MARKET FOR CONJUGATE VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)	87
TABLE 42 GLOBAL MARKET FOR RECOMBINANT/RDNA/DNA VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)	89
TABLE 43 GLOBAL MARKET FOR SUBUNIT VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)	92
TABLE 44 GLOBAL MARKET FOR TOXOID VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)	93
TABLE 45 GLOBAL MARKET FOR OTHER/COMBINATION VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)	95
TABLE 46 GLOBAL SALES OF ANIMAL HEALTH PRODUCTS BY MARKET LEADER, 2014-2016 (\$ MILLIONS)	100
TABLE 47 GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, THROUGH 2021 (\$ MILLIONS)	103
TABLE 48 GLOBAL MARKET FOR VACCINES FOR FOOD-PRODUCING ANIMALS BY REGION, THROUGH 2021 (\$ MILLIONS)	107
TABLE 49 GLOBAL MARKET FOR VACCINES FOR COMPANION ANIMALS BY REGION, THROUGH 2021 (\$ MILLIONS)	110
TABLE 50 GLOBAL MARKET FOR OTHER ANIMAL VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)	112
TABLE 51 GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE, 2015 (%)	113
TABLE 52 GLOBAL SALES OF ANIMAL VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)	115
TABLE 53 GLOBAL MARKET SHARES OF ANIMAL VACCINE SALES BY REGION, 2015 (%)	116
TABLE 54 LEADING MANUFACTURERS/ SUPPLIERS OF HUMAN VACCINES	118
TABLE 55 GLOBAL MARKET SHARE OF MANUFACTURERS OF HUMAN VACCINE, 2015 (%)	124
TABLE 56 LEADING MANUFACTURERS/SUPPLIERS OF ANIMAL VACCINES	126
TABLE 57 ANIMAL VACCINE MANUFACTURERS' GLOBAL MARKET SHARE, 2015 (%)	129
TABLE 58 HUMAN VACCINES BASED ON MICROORGANISM	132
TABLE 59 GLOBAL SALES OF HUMAN VACCINES FOR MENINGOCOCCAL/ PNEUMOCOCCAL DISEASES, THROUGH 2021 (\$ MILLIONS)	135
TABLE 60 GLOBAL MARKET SHARES OF TOP-SELLING MENINGOCOCCAL/ PNEUMOCOCCAL VACCINES, 2015 (%)	136
TABLE 61 GLOBAL SALES OF HUMAN VACCINES IN INFLUENZA DISEASES MARKET, THROUGH 2021 (\$ MILLIONS)	138
TABLE 62 GLOBAL MARKET SHARES OF TOP-SELLING INFLUENZA VACCINES, 2015 (%)	139
TABLE 63 GLOBAL MARKET FOR HUMAN VACCINES PEDIATRIC POLIO/PERTUSSIS/HIB DISEASES, THROUGH 2021 (\$ MILLIONS)	142

TABLE HEADING	PAGE NO.
TABLE 64 GLOBAL MARKET SHARES OF TOP-SELLING PEDIATRIC POLIO/PERTUSSIS/HIB VACCINES, 2015 (%)	143
TABLE 65 GLOBAL MARKET FOR HUMAN VACCINES IN ADULT/ADOLESCENT BOOSTER DISEASES, THROUGH 2021 (\$ MILLIONS)	144
TABLE 66 GLOBAL MARKET SHARES OF TOP-SELLING ADULT/ADOLESCENT BOOSTER VACCINES, 2015 (%)	145
TABLE 67 GLOBAL MARKET FOR HUMAN VACCINES FOR TRAVEL-RELATED AND OTHER ENDEMIC DISEASES, THROUGH 2021 (\$ MILLIONS)	148
TABLE 68 GLOBAL MARKET SHARES OF TOP-SELLING VACCINES FOR TRAVEL-RELATED AND OTHER ENDEMIC DISEASES, 2015 (%)	149
TABLE 69 GLOBAL MARKET FOR HUMAN VACCINES IN HPV, THROUGH 2021 (\$ MILLIONS)	151
TABLE 70 GLOBAL MARKET SHARES OF TOP-SELLING HPV VACCINES, 2015 (%)	152
TABLE 71 GLOBAL MARKET FOR HUMAN VACCINES IN ROTAVIRUS, THROUGH 2021 (\$ MILLIONS)	154
TABLE 72 GLOBAL MARKET SHARES OF TOP-SELLING ROTAVIRUS VACCINES, 2015 (%)	155
TABLE 73 GLOBAL MARKET FOR HUMAN VACCINES IN THE OTHER DISEASES SEGMENT, THROUGH 2021 (\$ MILLIONS)	157
TABLE 74 GLOBAL MARKET SHARES OF TOP-SELLING VACCINES IN THE OTHER DISEASES SEGMENT, 2015 (%)	158
TABLE 75 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY APPLICATION, 2015 (%)	159
TABLE 76 U.S. PATENTS ISSUED FOR VACCINES BY YEAR, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS)	162
TABLE 77 U.S. PATENTS BY TYPE OF VACCINES, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS)	163
TABLE 78 U.S. PATENTS BY ASSIGNEE'S COUNTRY, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS)	164
TABLE 79 GLOBAL PATENT SHARES BY PATENT HOLDER'S COUNTRY, JANUARY 2014-SEPTEMBER 2016 (%)	165
TABLE 80 U.S. PATENTS BY COMPANY, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS)	167
TABLE 81 U.S. PATENTS BY ASSIGNEE TYPE, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS)	168

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, 2014-2021 (\$ MILLIONS)	8
FIGURE 1 OVERVIEW OF HOW RNA-BASED VACCINES WORK	27
FIGURE 2 GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, 2014-2021 (\$ MILLIONS)	75
FIGURE 3 GLOBAL MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE, 2015 (%)	77
FIGURE 4 GLOBAL SALES OF HUMAN VACCINES BY REGION, 2014-2021 (\$ MILLIONS)	79
FIGURE 5 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY REGION, 2015 (%)	80
FIGURE 6 GLOBAL MARKET FOR ATTENUATED (LIVE) VACCINE BY REGION, 2014-2021 (\$ MILLIONS)	82
FIGURE 7 GLOBAL MARKET FOR INACTIVATED (KILLED) VACCINES BY REGION, 2014-2021 (\$ MILLIONS)	84
FIGURE 8 GLOBAL MARKET FOR CONJUGATE VACCINES BY REGION, 2014-2021 (\$ MILLIONS)	87
FIGURE 9 GLOBAL MARKET FOR RECOMBINANT/RDNA/DNA VACCINES BY REGION, 2014-2021 (\$ MILLIONS)	90
FIGURE 10 GLOBAL MARKET FOR SUBUNIT VACCINES BY REGION, 2014-2021 (\$ MILLIONS)	92
FIGURE 11 GLOBAL MARKET FOR TOXOID VACCINES BY REGION, 2014-2021 (\$ MILLIONS)	94
FIGURE 12 GLOBAL MARKET FOR OTHER/COMBINATION VACCINES BY REGION, 2014-2021 (\$ MILLIONS)	95
FIGURE 13 GLOBAL SALES OF ANIMAL HEALTH PRODUCTS BY MARKET LEADER, 2014-2016 (\$ MILLIONS)	100
FIGURE 14 GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, 2014-2021 (\$ MILLIONS)	103
FIGURE 15 GLOBAL MARKET FOR VACCINES FOR FOOD-PRODUCING ANIMALS BY REGION, 2014-2021 (\$ MILLIONS)	108
FIGURE 16 GLOBAL MARKET FOR VACCINES FOR COMPANION ANIMALS BY REGION, 2014-2021 (\$ MILLIONS)	110
FIGURE 17 GLOBAL MARKET FOR OTHER ANIMAL VACCINES BY REGION, 2014-2021 (\$ MILLIONS)	112
FIGURE 18 GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE, 2015 (%)	113
FIGURE 19 GLOBAL SALES OF ANIMAL VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)	115
FIGURE 20 GLOBAL MARKET SHARES OF ANIMAL VACCINE SALES BY REGION, 2015 (%)	116
FIGURE 21 GLOBAL MARKET SHARE OF MANUFACTURERS OF HUMAN VACCINE, 2015 (%)	124
FIGURE 22 ANIMAL VACCINE MANUFACTURERS GLOBAL MARKET SHARE, 2015 (%)	129
FIGURE 23 GLOBAL SALES OF HUMAN VACCINES FOR MENINGOCOCCAL/PNEUMOCOCCAL DISEASES, 2014-2021 (\$ MILLIONS)	135
FIGURE 24 GLOBAL MARKET SHARES OF TOP-SELLING MENINGOCOCCAL/PNEUMOCOCCAL VACCINES, 2015 (%)	136
FIGURE 25 GLOBAL SALES OF HUMAN VACCINES IN INFLUENZA DISEASES MARKET, 2014-2021 (\$ MILLIONS)	138
FIGURE 26 GLOBAL MARKET SHARES OF TOP-SELLING INFLUENZA VACCINES, 2015 (%)	139

FIGURE TITLE	PAGE NO.
FIGURE 27 GLOBAL MARKET FOR HUMAN VACCINES PEDIATRIC POLIO/PERTUSSIS/HIB DISEASES MARKET, 2014-2021 (\$ MILLIONS)	142
FIGURE 28 GLOBAL MARKET SHARES OF TOP-SELLING PEDIATRIC POLIO/PERTUSSIS/HIB VACCINES, 2015 (%)	143
FIGURE 29 GLOBAL MARKET FOR HUMAN VACCINES IN ADULT/ADOLESCENT BOOSTER DISEASES, 2014-2021 (\$ MILLIONS)	145
FIGURE 30 GLOBAL MARKET SHARES OF TOP-SELLING ADULT/ADOLESCENT BOOSTER VACCINES, 2015 (%)	145
FIGURE 31 GLOBAL MARKET FOR HUMAN VACCINES FOR TRAVEL-RELATED AND OTHER ENDEMIC DISEASES, 2014-2021 (\$ MILLIONS)	148
FIGURE 32 GLOBAL MARKET SHARES OF TOP-SELLING VACCINES FOR TRAVEL-RELATED AND OTHER ENDEMIC DISEASES, 2015 (%)	149
FIGURE 33 GLOBAL MARKET FOR HUMAN VACCINES IN HPV, 2014-2021 (\$ MILLIONS)	151
FIGURE 34 GLOBAL MARKET SHARES OF TOP-SELLING HPV VACCINES, 2015 (%)	152
FIGURE 35 GLOBAL MARKET FOR HUMAN VACCINES IN ROTAVIRUS, 2014-2021 (\$ MILLIONS)	154
FIGURE 36 GLOBAL MARKET SHARES OF TOP-SELLING ROTAVIRUS VACCINES, 2015 (%)	155
FIGURE 37 GLOBAL MARKET FOR HUMAN VACCINES IN THE OTHER DISEASES SEGMENT, 2014-2021 (\$ MILLIONS)	157
FIGURE 38 GLOBAL MARKET SHARES OF TOP-SELLING VACCINES IN THE OTHER DISEASES SEGMENT, 2015 (%)	158
FIGURE 39 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY APPLICATION, 2015 (%)	160
FIGURE 40 U.S. PATENTS ISSUED FOR VACCINES BY YEAR, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS)	163
FIGURE 41 U.S. PATENTS BY TYPE OF VACCINES, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS)	164
FIGURE 42 PATENT SHARES BY PATENT HOLDER'S COUNTRY, JANUARY 2014-SEPTEMBER 2016 (%)	166
FIGURE 43 U.S. PATENTS BY ASSIGNEE TYPE, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS)	168